Micromorphological observation of HLE cells under knockdown of Fascin using LV-SEM.

Med Mol Morphol

Department of Pathology, School of Medicine, Kochi University, 185-1, Kohasu, Oko-Cho, Nankoku, 783-8505, Japan.

Published: December 2023

Liver cancer is one of the most prevalent cancers in Japan with hepatocellular carcinoma (HCC) as the major histological subtype. Successful novel treatments for HCC have been reported; however, recurrences or metastasis may occur, which results in poor prognoses and high mortality of HCC patients. Fascin, an actin-bundling protein, regulates cell adhesion, migration, and invasion. Its overexpression positively correlates with poor prognosis of malignant tumors, and Fascin is considered as one of the tumor biomarkers and therapeutic target proteins. In this study, we attempted to reveal the relationship between Fascin and HCC using HLE, one of the human HCC cell lines. We performed the study with classical immunocytochemistry and recently developed techniques, such as wound-healing assay, spheroid cultivation, and low-vacuum scanning electron microscopy (LV-SEM). Non-Fascin-knockdown (FKD) cell spheroid had a regular spherical appearance with tight cell-cell connections, while FKD cell spheroid had an irregular shape with loose cell-cell connections. Cells of non-FKD spheroid presented fibrous protrusions on the cell surface, contrarily, cells of FKD spheroids showed bulbous-shaped protrusions. Morphological observation of FKD and non-FKD HLE spheroids were performed using LV-SEM. Our study may help to reveal the roles of Fascin in the process of HCC formation and its malignancy.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00795-023-00362-zDOI Listing

Publication Analysis

Top Keywords

fkd cell
8
cell spheroid
8
cell-cell connections
8
hcc
6
fascin
5
cell
5
micromorphological observation
4
observation hle
4
hle cells
4
cells knockdown
4

Similar Publications

Article Synopsis
  • In men with metastatic hormone-sensitive prostate cancer (mHSPC), new treatments help many live longer, but how well each person does can be really different.
  • Researchers are looking at a blood test that counts tiny cancer cells (CTCs) to see if it can help predict a patient’s survival.
  • They studied 503 men to see if the number of CTCs in their blood was linked to how long they lived and how well their treatment worked.
View Article and Find Full Text PDF
Article Synopsis
  • The pilot study investigated the safety and efficacy of daratumumab, a monoclonal antibody targeting CD38, in patients with muscle-invasive bladder cancer (MIBC) and metastatic renal cell carcinoma (mRCC).
  • In the MIBC group, one out of eight patients achieved a pathologic complete response with no toxicity events noted in either cohort, while the mRCC group showed no objective responses and a median progression-free survival of only 1.5 months.
  • Overall, the study concluded that while daratumumab was safe for use, its efficacy in these cancers was limited, with indications of targeted effects on CD38-expressing immune cells.
View Article and Find Full Text PDF

Importance: Clinical trial data on adjuvant therapy in patients with non-clear cell renal cell carcinoma (RCC) are scant.

Objective: To evaluate the effect of adjuvant everolimus after nephrectomy on recurrence-free survival (RFS) and overall survival (OS) in patients with localized papillary and chromophobe RCC.

Design, Setting, And Participants: This prespecified subgroup analysis of a phase 3 randomized clinical trial, EVEREST, included patients enrolled between April 1, 2011, and September 15, 2016.

View Article and Find Full Text PDF

The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies.

Crit Rev Oncol Hematol

August 2024

Vita-Salute San Raffaele University, Milan, Italy; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.

Article Synopsis
  • - Genitourinary cancers (GUCs) such as renal cell carcinoma, urothelial carcinoma, and prostate cancer have rapidly evolving treatments that can lead to significant skin-related side effects, referred to as cutaneous adverse events (AEs).
  • - A literature review analyzed various therapies, including immune checkpoint inhibitors and antiangiogenic drugs, finding common AEs like rashes and itching, with unique skin reactions linked to specific treatments.
  • - Recognizing and managing these dermatologic AEs is crucial, as they can affect patients' quality of life and treatment adherence, emphasizing the need for teamwork among healthcare providers in monitoring and addressing these skin issues.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!